The Med Spa Growth and Economics Playbook

Every client who walks in falls into one of three patterns. Premium clients follow a protocol: quarterly Botox, an annual filler review, a standing membership. Typical clients come back once or twice a year when they remember or when you remind them. Minimal clients are a single visit, often a promotion, who rarely reinvest.

The mix of those three tiers, not the treatment menu, is what determines five-year value. A spa with a narrow menu and a strong premium tier outperforms a spa with every device on the market and no system for moving clients up.

American Med Spa Association data backs the direction of this: repeat visits are already the norm and getting more so.

The industry itself is being carried by clients who come back, not by first-time promotional traffic. That makes the tier a client sits in the single highest-impact thing you can influence.

Segment your own client list by these three tiers before you plan a single promotion. Everything else in this guide, pricing, memberships, seasonal timing, assumes you know roughly what share of your book sits in each one.

The American Society of Plastic Surgeons's 2023 fee report puts the average hyaluronic acid (HA) filler cost at $715, down from $794 the year before, a real and fairly recent price compression worth knowing before you set your own rates. HA fillers had 5.3 million patients in 2024, up 1% year over year:

"6 to 12 months" describes the visible aesthetic effect of most HA fillers, not how long the material stays in the tissue, and treating those as the same thing is the most common overclaim in filler marketing.

A 2024 MRI-based review found HA material physically detectable in the mid-face for 2 to 15 years post-injection, well past when the visible lift fades. Tell clients the honest version: results look their best for 6 to 12 months, and product can still be present well beyond that, which is why over-injecting "to be safe" is a real risk, not just a cost issue.

Radiesse, a biostimulatory filler, is rated by its own manufacturer to last up to 2 years in the face. Sculptra, alongside HA fillers like Juvederm, Restylane, and RHA, collagen-stimulating rather than volumizing, showed 94% of patients with visible improvement through 24 months in its clinical extension study. Both durability numbers come from the manufacturers directly, which is as close to a primary source as this category gets.

The category those two belong to is also where the real growth is. ASPS itself now publishes patient-facing content on the trend, describing steady year-over-year demand growth for non-HA biostimulators. They aren't replacing HA fillers (HA still leads by volume, and biostimulators can't be dissolved the way HA can if something goes wrong) but they're winning specific jobs HA does poorly: larger-volume areas, jawline and cheek definition, and the kind of gradual collagen rebuild clients ask for by name now. If your treatment menu still treats biostimulators as a niche add-on, that's worth revisiting before a competitor positions around it first.

On the neurotoxin side, this is a real and growing market, not a commodity in decline.

AbbVie's Botox Cosmetic did $2.72 billion in 2024, still the category leader by a wide margin. Galderma's neuromodulator line is smaller but growing faster, evidence that clients are shopping between brands, not just deciding whether to get treated at all.

Filler clients split into three adherence patterns, and the split matters more than the average. Roughly 20% become high-adherence, progression clients: they start with hyaluronic acid (HA) and move into biostimulatory and eventually structural volume over time. About 60% are typical, maintaining one or two syringes a year in high-visibility areas. The remaining 20% are minimal, treating once for an occasion and rarely returning.

Modeled on real U.S. average pricing ($750 per HA syringe, $1,000 per biostimulatory vial, $6,000 per structural session), the five-year value gap between those three groups is enormous.

1. High-adherence, ~20% of clients. Year one often combines products: 4 HA syringes ($3,000) plus 2 biostimulatory vials ($2,000), roughly $5,000. Years two through five typically add 2 to 3 HA syringes a year ($6,000 to $9,000 total), one biostimulatory vial a year ($4,000 total), and one structural session ($6,000). Five-year value: $20,000 to $24,000.
2. Typical, ~60% of clients. Year one is about 2 syringes ($1,500). Years two through five hold at 1 to 2 syringes a year ($3,000 to $6,000 total). Five-year value: $4,500 to $7,500.
3. Minimal, ~20% of clients. One syringe in year one ($750), with at most a single touch-up over the following four years. Five-year value: about $1,500.

A 20% slice of your client list is worth roughly 15 times what your minimal slice is worth over five years. That gap is the entire business case for moving typical clients up a tier, not acquiring more minimal ones.

Build the membership and bundle structure in the next part around this math directly: a quarterly HA program to keep typical clients from lapsing to once a year, an annual biostimulatory review to introduce the second product category, and a treatment-mapping consult that gives high-adherence clients a reason to plan structural work instead of deciding on the spot.

We fact-checked the clinical citations commonly used to sell filler durability and found three that don't hold up: a "Micheels" lip study, a "Monheit 2013" nasolabial fold comparison, and a "Dermatology Review 2024" longevity report. None of them trace to a real, findable paper. This happens constantly in aesthetics marketing, a citation gets rounded, misattributed, or invented once, and then copied for years.

Here's what the real studies behind those same claims found.

On lip filler with Tri-Hyal technology, the real paper is Kestemont et al., Aesthetic Surgery Journal Open Forum, 2025: 73 patients, sustained lip volume through 18 months.

On comparing major HA brands in the nasolabial folds, the real paper is Prager et al., Dermatologic Surgery, 2012: a split-face study finding Belotero, Restylane, and Juvéderm essentially equivalent over 12 months.

On how long filler material persists, the real paper is the Master et al. MRI review, 2024 covered in the last chapter.

Cite the real studies, or don't cite a study at all and say plainly that a claim is based on clinical experience. A wrong citation is worse than no citation, because it's the kind of thing a client's own research turns up.

The Zenoti 2026 Beauty and Wellness Benchmark Report, built from real med spa platform data, shows how wide the gap runs between an average location and a top-performing one:

That gap between the median and the top decile isn't explained by fancier equipment. It's explained by how deliberately a practice moves clients from a single visit into a standing relationship.

The clearest illustration is a single-practice case study published by AmSpa on the Dallas Plastic Surgery Institute's membership program: member visit frequency rose from 1.7 to 3.03 visits per year.

One practice, not an industry average, so treat the exact number as illustrative. The direction (a membership converts occasional visits into a habit) is the part worth building around.

A working membership does three things: bundles a core service (Botox, a facial, a peel) into a flat monthly rate, includes a real discount on add-ons so upgrading feels like a deal rather than upselling, and bills automatically so retention isn't dependent on the client remembering to rebook.

Stacking two services in one visit is another lever for the same tier-moving goal: RF microneedling (Morpheus8, VirtueRF, or SkinPen) with PRP for faster healing and more collagen response, a HydraFacial or DiamondGlow facial followed by LED light therapy in one sitting, or skin tightening paired with body contouring so a client solves two goals in one appointment instead of two separate bookings.

Running this on a real CRM is what turns tier-tracking from a spreadsheet someone forgets into a system that flags who's ready to move up, automatically.

The tiering framework from earlier in this guide, premium clients who stay on protocol, typical clients who return occasionally, minimal clients who complete one round and stop, isn't specific to fillers or body contouring. It's how to think about every category on your menu. Four categories are worth naming on their own, since they don't get the deep model treatment elsewhere in this guide but follow the identical pattern.

Laser hair removal. Premium clients add zones over time and keep an annual touch-up going after the initial series. Typical clients complete one area and stop returning once it's done, there's no natural recurring need the way there is with injectables. A loyalty credit for adding a second zone, or a referral discount, is the practical lever for moving someone up a tier here, since the treatment itself has a natural endpoint.

Hair restoration (PRP, PRF, exosomes). This category runs on completed protocols, not open-ended maintenance. Premium clients finish the full series and add booster products or adjunct treatments along the way. Typical clients stop after the initial round. The conversion lever is structured follow-up with visual progress documentation, hair regrowth is slow enough that clients lose motivation without proof it's working.

Laser resurfacing (Fraxel, HALO, CoolPeel). Results fade gradually as skin ages and re-sustains sun exposure, which makes this a genuinely annual category for a premium client willing to maintain results rather than chase a single dramatic outcome. Education is the conversion tool: clients who understand resurfacing as a progressive, ongoing investment (not a one-time fix) are the ones who rebook the following year.

Functional medicine and hormone therapy (BioTE, testosterone, estrogen replacement, medical weight loss). This is the longest retention horizon on the entire menu. Clinician-supervised protocols with regular lab monitoring keep premium clients engaged for years, not visits, and monthly subscription billing is a natural fit given the ongoing clinical relationship. Medical weight loss belongs here as its own line, not folded into the GLP-1 demand-headwind discussion elsewhere in this guide: a client on a supervised semaglutide or tirzepatide protocol is a recurring clinical relationship with its own retention economics, separate from how GLP-1 adoption is reshaping body contouring demand.

None of these four need a full five-year dollar model to be useful. What they need is the same discipline applied to fillers and body contouring: know which tier a client is in, and build the follow-up system that matches it.

Two of these categories are priced per session, like fillers. Two are priced as ongoing subscriptions, which changes the math entirely: the driver of five-year value isn't how many modalities a client combines, it's how many months they stay on the program. Both approaches use the same premium/typical/minimal framing as the rest of this guide.

Laser hair removal. A typical starting package (6 to 8 sessions across 2 to 3 zones) runs around $1,400. This is the lowest-ceiling category on the list: LHR has a natural stopping point once hair reduction is complete, and no amount of program design changes that.

• Premium (~20%): adds zones over time and keeps an annual touch-up going. Five-year value around $3,200.
• Typical (~55%): completes the package and returns once for a touch-up. Five-year value around $1,700.
• Minimal (~25%): does a partial series on one area and doesn't return. Five-year value around $800.

Hair restoration (PRP, PRF, exosomes). An initial series (3 to 4 sessions) runs around $2,400.

• Premium (~20%): adds booster sessions and adjunct products annually. Five-year value around $5,600.
• Typical (~55%): completes the series and returns for one maintenance round every other year. Five-year value around $3,800.
• Minimal (~25%): stops after the initial series. Five-year value around $2,400.

Laser resurfacing (Fraxel, HALO, CoolPeel). Pricing spans a real range by device: CoolPeel sessions run around $600, HALO and Fraxel run $1,000 to $2,000 depending on treatment area.

• Premium (~20%): treats this as an annual maintenance category on HALO or Fraxel. Five-year value around $7,500.
• Typical (~55%): does an initial round and one repeat around year three. Five-year value around $3,300.
• Minimal (~25%): does a single CoolPeel series and stops. Five-year value around $1,800.

Medical weight loss (semaglutide, tirzepatide). Most med spas run this on compounded GLP-1 pricing, around $350 a month, well below the $1,000-plus list price for brand-name Ozempic, Wegovy, or Zepbound. This is the highest-value category on the entire menu by a wide margin, and also the one with the most real attrition: GLP-1 discontinuation within the first year is well documented and common, driven by side effects, cost, and reaching a goal weight and stopping.

• Premium (~20%, long-term maintenance): stays on the program close to four years within the five-year window. Five-year value around $16,800.
• Typical (~55%): stays 12 to 18 months. Five-year value around $5,250.
• Minimal (~25%): tries it for a few months and discontinues. Five-year value around $1,400.

Hormone therapy (BioTE pellets, testosterone, estrogen). A pellet insertion cycle, procedure fee plus pellets plus labs, runs around $1,100, with women typically on a 2-cycle annual schedule and men closer to 3 to 4.

• Premium (~20%): stays on consistent, clinician-supervised protocols for the full five years. Five-year value around $13,800.
• Typical (~55%): runs a lighter schedule and often tapers after a couple of years. Five-year value around $8,250.
• Minimal (~25%): tries one year and stops. Five-year value around $2,750.

None of these numbers are a promise, the same caveat that applies to the filler and body contouring models applies here. What they tell you is where to put your attention: medical weight loss and hormone therapy carry more five-year value per client than fillers or body contouring, but they also carry real attrition risk that the per-session categories don't. A membership structure that assumes a GLP-1 client stays five years is optimistic in a way a filler membership isn't.

Sun exposure, holidays, and event calendars drive demand shifts that repeat every year. Laser treatments and resurfacing sell better in fall and winter, when clients aren't worried about sun exposure on treated skin. Injectables spike around the holidays. Body contouring peaks ahead of spring and summer. Plan each month's push at least a quarter ahead, and tie every offer to a membership upgrade or a bundle rather than a flat discount, which trains clients to wait for one. Heavy discounting and Groupon-style flash sales are fading for a reason: they buy one-time buyers, not clients, and discount fatigue trains your list to wait you out.

• January. Lead with laser hair removal and body contouring. "New Year" transformation packages, tied to a membership rather than a one-off deal. Run it as testimonial-driven social posts and email, real client transformations, not stock photography.
• February. Lead with injectables and rejuvenating facials. Couples packages and gift cards work well around Valentine's Day. An Instagram giveaway timed to the week of the 14th outperforms a plain discount post.
• March. Last call on laser hair removal before bare-skin season, plus chemical peels. Frame it as a deadline, not a discount. A countdown ad in the last two weeks of the month does more work than a static post.
• April. Body contouring and cellulite reduction, positioned as "beach ready" packages timed 8 to 12 weeks ahead of summer, since most modalities need that runway to show results. Before-and-after photo campaigns work well here (keep them within the platform's ad-content rules, covered later in this guide).
• May. Summer skincare: HydraFacial, light peels, SPF retail bundles. Pair with a local partner if you can. Sun-safety education, not just product promotion, fits the month's intent better than a hard sell.
• June. Quick-turnaround treatments and injectables for clients prepping for summer events and vacations, minimal downtime is the selling point. A short social video built around "back to your desk in an hour" outperforms a static before-and-after here.
• July. Hydration facials and gentle maintenance treatments. A slower month for new-client acquisition, so use it for check-ins with existing members. An Instagram Stories Q&A answering the questions clients ask works better than a promotional push in a slow month.
• August. Post-summer recovery: restoration facials, antioxidant treatments for sun exposure. Good month for a re-engagement email to anyone who went quiet over the summer. Run it as a short drip, not a single blast, education first, offer second.
• September. Laser season starts. IPL and fractional resurfacing, framed as reversing summer damage.
• October. Peak laser season. Bundle laser packages and push harder here than any other laser month. Point any paid traffic at a dedicated fall-laser landing page rather than your general services page.
• November. Injectables and quick facial refreshes ahead of the holidays. This is the month to run your best offer of the year, holiday demand is real and time-boxed. Name it: a Black Friday medspa promotion converts better than an unnamed "best offer of the year."
• December. Gift cards and year-end membership sign-ups. A gift card sold in December is a client acquisition channel for January. A "12 Days of Beauty" social series through the back half of the month keeps the account active while most competitors go quiet.

Track what converted at the end of each cycle, not just what ran, and adjust next year's calendar accordingly. A promo that felt right but didn't move bookings shouldn't survive a second December just because it ran the first one.

None of this replaces the tier-and-membership work from the rest of this guide. It just tells you which month to point it at.

The American Society of Plastic Surgeons's 2024 statistics confirmed what a lot of med spas felt on the floor: non-invasive fat reduction procedures fell hard as GLP-1 weight-loss drugs went mainstream. Growing awareness of paradoxical adipose hyperplasia (PAH), a rare but real side effect where treated fat cells enlarge instead of shrinking, is part of the same headwind.

That's the number every industry blog quotes. What most of them miss is what ASPS itself named as one of the defining trends of 2026: the category didn't just shrink, it pivoted.

"GLP-1 makeovers," combination protocols pairing skin-tightening and contouring with the aesthetic side effects of rapid weight loss (loose skin, volume loss in the face), are now one of the fastest-growing segments in the category. A client on Ozempic or Zepbound isn't a lost body contouring client. She's a different kind of body contouring client, one who needs a different treatment plan than the pre-GLP-1 playbook assumed.

A 2015 systematic review in Plastic and Reconstructive Surgery (Ingargiola et al.) found cryolipolysis reduces fat by roughly 15 to 28% with a strong safety profile across the studies reviewed. The mechanism is permanent, cryo destroys the treated fat cells outright, so results depend more on the client's weight staying stable afterward than on any single treatment variable. That's also why re-treatment is selective rather than routine.

For HIFEM alone (plain Emsculpt, not Neo), a one-year follow-up published in the Aesthetic Surgery Journal (Kinney & Kent, 2020) found sustained fat reduction and muscle thickness after a 4-session series, though muscle strength gains fade without continued resistance training, the device builds tissue, not a workout habit. A 2021 multicenter MRI study in Dermatologic Surgery (Jacob, Kent & Ibrahim) confirmed the same pattern for the combined HIFEM-plus-RF protocol Emsculpt Neo uses, at 3 and 6 months.

The durability data on the treatments themselves hasn't changed. Cryolipolysis results have been documented holding at 6 and 9 years post-treatment in long-term case follow-up, genuinely durable once fat cells are destroyed. Emsculpt Neo's combined muscle-and-fat protocol shows results in the range of 25 to 30% improvement in peer-reviewed studies, sustained several months post-treatment.

The market is still there, asking a different question than it was two years ago.

Set expectations with the evidence you have, not the marketing version. No randomized trial shows every patient returning for annual full treatment cycles over 3 to 5 years, that pattern is inferred from clinic booking data, not proven in the literature. When you hear "maintenance every few months" from a device rep or a competitor's marketing, read it as occasional boosters, not a full repeat series, the two get conflated constantly. Cryo is the durable, evidence-backed choice with rare re-treatment need. HIFEM and HIFEM-plus-RF deliver real, measured results that hold for months, with boosters positioned as optional, not mandatory upsells.

Body contouring clients split into three adherence patterns too, though the split runs less top-heavy than fillers: roughly 15 to 25% are premium adherence (motivated, willing to reinvest with semiannual boosters), 50 to 60% are typical (complete an initial plan, return once a year or every other year), and 25 to 35% do minimal maintenance (the initial series only, reinvesting only if their weight changes or a new area comes up).

Modeled on real U.S. average pricing (a cryolipolysis plan around $2,400, a HIFEM or Neo series around $3,600, a cryo touch-up around $800, a HIFEM booster around $900), here's what five years looks like by tier.

1. Premium adherence, ~15-25% of clients. Year one combines a cryo plan and a HIFEM/Neo series: $2,400 plus $3,600, or $6,000. Years two through five add a cryo touch-up annually ($800 x 4 = $3,200) and two HIFEM/Neo boosters a year ($900 x 2 x 4 = $7,200). Five-year value: $16,400, ranging $14,000 to $20,000.
2. Typical, ~50-60% of clients. One full plan in year one, around $3,000. One booster a year, or one cryo touch-up every other year, roughly $700 a year, for years two through five ($2,800). Five-year value: $5,800, ranging $5,000 to $7,000.
3. Minimal, ~25-35% of clients. One plan in year one ($2,400), with 0 to 1 touch-ups total after that ($0 to $800 depending on whether that one touch-up happens). Five-year value: $2,800, ranging $2,400 to $3,200.

The model has real knobs you can adjust for your own market: booster adoption rate (premium clients averaging 2 HIFEM boosters a year plus 1 cryo touch-up, typical clients 1 booster or touch-up every other year), local pricing ($600 to $1,200 per cryo cycle, $700 to $1,500 per Emsculpt session are both normal ranges), and how many modalities a client combines.

The knob worth building in now is the market headwind from The Body Contouring Pivot. A base case using the segment splits above (roughly 60% typical, 25% minimal, 15% premium) blends to about $6,500 per client over five years. An optimistic case, with stronger premium adoption, runs closer to $8,000 or more. A downside case, applying a 10 to 20% volume haircut for the GLP-1 effect on demand, lands closer to $5,000.

None of these numbers are a promise. They're a planning tool: segment your own client list into the three tiers, plug your local pricing into the knobs above, and you have a defensible five-year forecast instead of a guess.

Map your membership structure to these same three tiers instead of running one generic plan for everyone. A Premium Track (semiannual boosters plus an annual touch-up, billed monthly) fits the 15 to 25% who'll use it. A Moderate Track (one annual check-in, one booster included) fits the typical majority. A Minimal Track (as-needed touch-ups, no recurring commitment) keeps the bottom tier from feeling oversold into a plan they won't use.

Outcomes also depend on the client, not just the device. Stable weight, regular exercise, and reasonable nutrition all influence how long results hold, and positioning your practice as a partner in sustaining the result, not just the provider of the initial treatment, is part of what makes the premium tier renew. Track five-year LTV by tier as a core planning metric, a system like Pulse can pull this automatically from booking and payment history instead of you rebuilding the math by hand every quarter.

Botox and botulinum toxin sit on Google's Restricted Drug Terms list, tied to the Healthcare and Medicines policy. Because it's a prescription drug, that requirement applies whether or not you prescribe it remotely. If your ad copy or your landing page names Botox, Google requires Healthcare and Medicines certification, and in practice that almost always means LegitScript certification too, even for a standard in-office clinic that only injects and never dispenses or prescribes online. Uncertified ads that name the drug get disapproved on sight.

Two separate policies do apply directly, and they're the ones worth knowing cold. Before-and-after images are banned under Google's Clickbait Ads policy, not the healthcare policy most people assume, which explicitly prohibits ads using before-and-after images to promote significant alterations to the human body. And unrealistic outcome claims ("results in 24 hours," guaranteed results) fall under the Misrepresentation policy, which bans claims that entice with an improbable result, even one that's technically possible but not typical.

If you do run telemedicine consultations or ship prescription product, LegitScript maintains a specific Medical Spas certification category covering injectables, dermal fillers, and hormone therapy, and it's the accreditor Google recognizes for that tier.

Get certified if your business model needs it. Don't assume every med spa does, and don't run a before-and-after campaign assuming it falls under a different rule than it does.

Two terms worth being precise about: an ad group is a container holding one set of ads and keywords aimed at a single theme. A search term is the actual phrase someone typed, which Google matches against your keywords. Confusing the two is how campaigns end up with one bloated ad group covering five treatments and converting none of them well.

Once you're certified, structure matters as much as compliance. Build one single-theme ad group per treatment area ("Botox for forehead lines," not "Botox" broadly), so every keyword, ad, and landing page in that group speaks to the same search intent. That discipline lifts Quality Score and lowers cost per click on its own.

Write the copy to describe the outcome, not the promise: "support smoother skin" or "minimize movement lines" clears review far more reliably than "erase wrinkles." A generic-phrasing workaround, using "wrinkle relaxer" instead of the brand name, sometimes lets an uncertified ad run, but it draws frequent disapprovals. Get certified first rather than betting on the workaround.

A worked example: "Smooth Frown Lines with Expert Injectors" as the headline, "Book a consult with a licensed provider. Individual results may vary." as the description, clears review and still sells. Lead with what's true and checkable, FDA-approved product, licensed provider, appointment length, rather than the outcome claim itself. Any time you reference clinical data or show a result, attach the disclaimer plainly instead of burying it in fine print. And skip the graphic close-ups, a needle mid-injection reads as clinical and cold, not reassuring. A clean shot of the treatment room does more to convert.

Getting the compliance layer right protects the paid ads account you've already built. Everything upstream of that, getting found locally and converting the clicks you earn, is covered in How to Win the Map Pack and How to Convert and Retain.

Cosmetic procedure ads on Meta fall under its Health and Wellness policy, not one of the four legally defined Special Ad Categories (Credit, Employment, Housing, and Social Issues, Elections or Politics). That distinction matters mechanically: those four categories restrict who you can target. Health and Wellness restricts what your ad can say and show, and increasingly, what happens to your conversion data behind the scenes.

Three creative rules cause most of the rejections. Cosmetic and injectable ads must target people 18 or older, set directly in your ad-set audience controls. Before-and-after comparisons are banned for Botox, fillers, and anti-aging content outright, close-up or zoomed-in result shots are allowed, side-by-side comparisons are not. Weight-loss and body-contouring before-and-afters are banned the same way, with a narrow carve-out for fitness-class content. General cosmetic procedures (skin rejuvenation, non-injectable treatments) can use before-and-after at 18+, as long as the copy doesn't lean on what Meta calls negative self-perception tactics, copy that implies something is wrong with the viewer's appearance rather than describing the treatment.

Name the treatment, not the drug. Meta's ad-review models flag unauthorized use of specific drug brand names, Botox, Ozempic, Wegovy, used directly in ad copy. "Neuromodulator treatment" or "medical weight loss" clears review more reliably than the brand name itself, even when the brand name is accurate.

Meta has no LegitScript-equivalent requirement for injectables. Its Drugs and Pharmaceuticals policy requires LegitScript certification for online pharmacies, telehealth providers, and CBD advertisers, not for aesthetic medicine or injectables. Compliance here runs through Meta's own internal ad review and Restricted Content classification, with no third-party certifier in the loop, a real mechanical difference from Google Ads, where LegitScript certification is the actual gate.

The bigger risk in 2026 is the ad that keeps running while Meta stops counting the bookings it drives. Since January 2025, Meta also classifies advertiser domains into restricted data categories, Health and Wellness, and separately Drugs and Pharmaceuticals if you offer GLP-1 services, at the pixel and Conversions API level. This is independent of ad-creative review. A treatment-specific URL slug (a page called /services/botox-treatment, for instance) or booking-form language that names a procedure can get your domain classified as restricted, which filters or blocks Purchase and Lead conversion events with no rejection notice at all. The ad keeps running and spending. Your reported bookings just drop, with nothing flagging it.

Per a 2026 analysis of med spa ad accounts, these are two separate problems with two separate fixes. Fixing your ad creative (dropping brand names, removing before-and-afters) solves the rejection problem. It does nothing for the domain-level data restriction, which requires reviewing what your landing page URLs and booking-form fields say, not just what your ad says.

If your Meta ad account shows healthy spend but conversion numbers that don't match what your front desk is booking, check domain classification before you assume the campaign itself is underperforming.